Global Mesenchymal Stem Cells Market, By Type (Autologous, Allogeneic), Product type (Human MSC, Mouse MSC, Rat MSC), Source of Isolation (Bone Marrow, Cord Blood, Peripheral Blood, Fallopian Tube, Fetal Liver, Lung, Adipose Tissues), Indication (Bone & Cartilage Repair, Cardiovascular Disease, Inflammatory & Immunological Diseases, Liver Diseases, Cancer, GvHD, Others), Application (Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies, Others), End-Users (Clinic, Hospital, Others) – Industry Trends and Forecast to 2030.
Mesenchymal Stem Cells Market Analysis and Size
Increased use of mesenchymal stem cells due to the increasing geriatric population, rise in the prevalence of chronic diseases, growing government initiatives, rising investment in stem cell biology, advancement in treatment options, and rising awareness are the factors that will expand the global mesenchymal stem cells market. Rising R&D activities and a growing volume of orthopedic procedures will provide beneficial opportunities for the global mesenchymal stem cells market in the forecast period of 2023-2030.
Data Bridge Market Research analyses that the global mesenchymal stem cells market which was USD 89.25 million in 2022, is expected to reach USD 132.81 million by 2030, and is expected to undergo a CAGR of 5.2% during the forecast period 2023-2030. This indicates that the market value. “Hospital” dominates the end-user segment of the global mesenchymal stem cells market owing to the wide range of products applications there. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Mesenchymal Stem Cells Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2014-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Autologous, Allogeneic), Product type (Human MSC, Mouse MSC, Rat MSC), Source of Isolation (Bone Marrow, Cord Blood, Peripheral Blood, Fallopian Tube, Fetal Liver, Lung, Adipose Tissues), Indication (Bone & Cartilage Repair, Cardiovascular Disease, Inflammatory & Immunological Diseases, Liver Diseases, Cancer, GvHD, Others), Application (Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies, Others), End-Users (Clinic, Hospital, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Lonza (Switzerland),Thermo Fisher Scientific Inc. (U.S.), Bio-Techne (U.S.), ATCC (American Type Culture Collection) (U.S.),Merck KGaA (Germany), PromoCell GmbH (Germany), Genlantis, Inc. (U.S.), Celprogen Inc. (U.S.), Cell Applications, Inc. (U.S.), Cyagen Biosciences (U.S.), Axol Bioscience Ltd. (U.K.)
|
|
Market Opportunities
|
|
Market Definition
Mesenchymal stem cells are adult stem cells whose main function is to repair and replace damage tissue. They show high potential for tissue repair and are isolated from other tissues such as bone marrow, cord blood, peripheral blood, fallopian tube, fetal liver, lung, and adipose tissues. They are a renewable source for the substitution of cells and tissues to treat diseases.
Global Mesenchymal Stem Cells Market Dynamics
Drivers
- Increasing Prevalence of Chronic Diseases
The rising incidence of chronic diseases such as diabetes, cardiovascular diseases, and orthopaedic disorders is a major driver of the MSCs market. MSCs hold promise for regenerative therapies to treat these conditions effectively.
Such global prevalence of disease and their increasing cases with most of the population in the majority of countries turns towards older age contribute to new research and development in musculoskeletal disease which is expected to drive the global mesenchymal stem cells market.
- Rising Number of Geriatric Population
Expanding geriatric population worldwide is predicted to favour the mesenchymal stem cells demand as this population is more prone to develop diseases. The number of persons above 65 years is projected to double in the coming years. The global aging population is more susceptible to age-related diseases and conditions, creating a greater demand for treatments that can address these health issues. MSC-based therapies hold promise in addressing age-related degenerative diseases, which can foster the demand for the mesenchymal stem cells across the globe.
- Increasing Clinical Trials and Research Initiatives
There has been a surge in clinical trials and research studies exploring the therapeutic potential of MSCs in various medical fields, including oncology, neurology, and autoimmune diseases. This research drives the demand for MSCs and related products.
Moreover, regenerative medicine, which focuses on repairing or replacing damaged tissues and organs, has gained significant attention. MSCs have emerged as a promising tool for regenerative therapies, driving demand for their isolation, expansion, and characterization which will further act as driver that will lead to the growth of the global mesenchymal stem cells market in the above mentioned projected timeframe.
Opportunity
- Increasing Technological Advancements
Advances in cell culture techniques, bioprocessing, and cell characterization methods have improved the scalability and efficiency of MSC production, making them more accessible for research and clinical applications owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2023 to 2030.
Additionally, both public and private investments in stem cell research and regenerative medicine have risen significantly. Funding supports research and development activities related to MSCs and their applications. This will further expand the market's growth rate in the future.
Restraint/Challenge
- Standardization and Quality Control
On the other hand, maintaining consistent quality and characteristics of MSCs across different batches is expected to obstruct market growth. Standardization and quality control measures are necessary to ensure the reliability and reproducibility of results in research and clinical applications. Moreover, high cost of treatment and lack of therapeutic advancement related to vitro properties of stem cells is expected to become the biggest and foremost challenge for the growth of the market in the forecast period of 2023-2030.
This global mesenchymal stem cells market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global mesenchymal stem cells market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In July 2021, A worldwide licensed agreement and strategic collaboration between Minovia Therapeutics, Ltd. and Astellas Pharma, Inc. were established for the development of cutting-edge stem cell therapy programs for illnesses brought on by mitochondrial malfunction. The partnership intends to accelerate the development of allogeneic mitochondrial cell therapy initiatives. The two businesses will collaborate to investigate potential cell treatment program prospects using Astellas' genetically modified, induced pluripotent stem cells and Minovia's MAT platform technology
Global Mesenchymal Stem Cells Market Scope
The global mesenchymal stem cells market is segmented on the basis of type, product type, source of isolation, indication, application, and end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Autologous
- Allogeneic
Product Type
- Human MSC
- Mouse MSC
- Rat MSC
Source of Isolation
- Bone Marrow
- Cord Blood
- Peripheral Blood
- Fallopian Tube
- Fetal Liver
- Lung
- Adipose Tissues
Indication
- Bone & Cartilage Repair
- Cardiovascular Disease
- Inflammatory & Immunological Diseases
- Liver Diseases
- Cancer
- GvHD
- Others
Application
- Disease Modelling
- Drug Development & Discovery
- Stem Cell Banking
- Tissue Engineering
- Toxicology Studies
- Others
End-Users
- Clinic
- Hospital
- Others
Global Mesenchymal Stem Cells Market Analysis/Insights
The global mesenchymal stem cells market is analyzed and market size insights and trends are provided by country, type, product type, source of isolation, indication, application, and end-users as referenced above.
The countries covered in the global mesenchymal stem cells market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the global mesenchymal stem cells market due to the presence of major key players, increased R&D spending, availability of advanced research facilities, growing government initiatives, and increasing awareness towards health in this region.
Asia-Pacific is expected to grow at the highest growth rate during the forecast period of 2023 to 2030 owing to the increasing research and development activities, rising investment in the healthcare infrastructure, and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Mesenchymal Stem Cells Market Share Analysis
The global mesenchymal stem cells market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global mesenchymal stem cells market.
Some of the major players operating in the global mesenchymal stem cells market are:
- Lonza (Switzerland)
- Thermo Fisher Scientific Inc. (U.S.)
- Bio-Techne (U.S.)
- ATCC (American Type Culture Collection (U.S.)
- Merck KGaA (Germany)
- PromoCell GmbH (Germany)
- Genlantis, Inc. (U.S.)
- Celprogen Inc. (U.S.)
- Cell Applications, Inc. (U.S.)
- Cyagen Biosciences (U.S.)
- Axol Bioscience Ltd. (U.K.)
SKU-